Adjunct Therapy with Ipragliflozin Exerts Limited Effects on Kidney Protection in Type 1 Diabetes: A Retrospective Study Conducted at 25 Centers in Japan (IPRA-CKD)

Nakamura, Yuta; Horie, Ichiro; Yano, Hiroshi; Nomoto, Hiroshi; Fukui, Tomoyasu; Yuyama, Yoshihiko; Kawamura, Tomoyuki; Ueda, Mariko; Yamamoto, Akane; Hirota, Yushi; Kusunoki, Yoshiki; Nishida, Kenro; Sekiguchi, Dan; Maeda, Yasutaka; Minami, Masae; Nagayama, Ayako; Iwata, Shimpei; Minagawa, Hitomi; Furukawa, Shinya; Miyake, Teruki; 上野, 浩晶; ウエノ, ヒロアキ; Ueno, Hiroaki; Chinen, Rei; Nakayama, Yoshiro; Masuzaki, Hiroaki; Miyachi, Yasutaka; Okada, Yosuke; Okamoto, Mitsuhiro; Ono, Kaoru; Tanaka, Ken Ichi; Kurozumi, Akira; Sakai, Takenori; Yamasaki, Hironori; Yasui, Jun Ichi; Ito, Ayako; Kawakami, Atsushi; Abiru, Norio

doi:https://doi.org/10.3390/biomedicines13061287

WEKO3

lat lon distance

[[sub_check.contents]]

[[sub_radio.contents]]

Field does not validate

[[sub_attr.contents]]　

インデックスツリー

アイテム

Adjunct Therapy with Ipragliflozin Exerts Limited Effects on Kidney Protection in Type 1 Diabetes: A Retrospective Study Conducted at 25 Centers in Japan (IPRA-CKD)

http://hdl.handle.net/10458/0002001694

名前 / ファイル	ライセンス	アクション
Fulltext (3.1 MB)

アイテムタイプ

学術雑誌論文 / Journal Article(1)

公開日

2025-08-27

タイトル

Adjunct Therapy with Ipragliflozin Exerts Limited Effects on Kidney Protection in Type 1 Diabetes: A Retrospective Study Conducted at 25 Centers in Japan (IPRA-CKD)

言語

eng

キーワード

言語

キーワード

chronic kidney disease

キーワード

言語

キーワード

ipragliflozin

キーワード

言語

キーワード

renal outcome

キーワード

言語

キーワード

SGLT2 inhibitor

キーワード

言語

キーワード

type 1 diabetes

資源タイプ

journal article

アクセス権

open access

著者

Nakamura, Yuta
Horie, Ichiro
Yano, Hiroshi
Nomoto, Hiroshi
Fukui, Tomoyasu
Yuyama, Yoshihiko
Kawamura, Tomoyuki
Ueda, Mariko
Yamamoto, Akane
Hirota, Yushi
Kusunoki, Yoshiki
Nishida, Kenro
Sekiguchi, Dan
Maeda, Yasutaka
Minami, Masae
Nagayama, Ayako
Iwata, Shimpei
Minagawa, Hitomi
Furukawa, Shinya
Miyake, Teruki
上野, 浩晶

WEKO 33888
e-Rad_Researcher 00381062

ja	上野, 浩晶宮崎大学
ja-Kana	ウエノ, ヒロアキ
en	Ueno, Hiroaki University of Miyazaki

Search repository

Chinen, Rei
Nakayama, Yoshiro
Masuzaki, Hiroaki
Miyachi, Yasutaka
Okada, Yosuke
Okamoto, Mitsuhiro
Ono, Kaoru
Tanaka, Ken Ichi
Kurozumi, Akira
Sakai, Takenori
Yamasaki, Hironori
Yasui, Jun Ichi
Ito, Ayako
Kawakami, Atsushi
Abiru, Norio

抄録

内容記述タイプ

Abstract

内容記述

Background/Objectives: While sodium–glucose cotransporter 2 (SGLT2) inhibitors have demonstrated additional non-glycemic benefits for renal protection in individuals with type 2 diabetes, less evidence is available for those with type 1 diabetes (T1D). To determine whether the adjunctive use of the SGLT2 inhibitor ipragliflozin confers kidney protection in individuals with T1D, we retrospectively analyzed data from a real-world cohort examined at 25 centers in Japan. Methods: We enrolled 359 subjects aged 20–74 years with T1D (IPRA group: 159 ipragliflozin users; control [CTRL] group: 200 non-users). The primary outcome was changes in the estimated glomerular filtration rate (eGFR) from baseline to 24 months after the initiation of ipragliflozin. The secondary outcomes were all other changes, including the urinary albumin–creatinine ratio (UACR) and urinary protein–creatinine ratio (UPCR). Results: The IPRA group’s eGFR decline slopes were 0.79 mL/min/1.73 m2/year milder than the CTRL group’s after propensity score matching, but this difference was not significant. The subjects complicated by chronic kidney disease (CKD) defined as UACR ≥ 30 mg/g and/or UPCR ≥ 0.5 g/g and/or eGFR < 60 mL/min/1.73 m2 showed changes in UPCR (g/g) from baseline to 24 months that were significantly lower in the IPRA group (−0.27 ± 1.63) versus the CTRL group (0.18 ± 0.36) (p = 0.016). No significant increase in adverse events (including severe hypoglycemia and hospitalization due to ketosis/ketoacidosis or cardiovascular diseases) was observed in the IPRA group. Conclusions: Adjunctive treatment with ipragliflozin exerted potential renal benefits by decreasing proteinuria in T1D subjects with CKD. Further investigations are required to determine whether its additional benefits exceed the increased risk of ketoacidosis.

言語

書誌情報

en : Biomedicines

巻 13, 号 6, p. 1287, 発行日 2025-05-23

出版者

MDPI

言語

ISSN

収録物識別子タイプ

EISSN

収録物識別子

22279059

DOI

Versions

Ver.1

2025-08-27 07:20:52.314333

Show All versions

Cite as

Other

エクスポート

OAI-PMH

JPCOAR 2.0
JPCOAR 1.0
DublinCore
DDI

Other Formats

メニューを最小化

インデックスリンク

インデックスツリー

アイテム

Adjunct Therapy with Ipragliflozin Exerts Limited Effects on Kidney Protection in Type 1 Diabetes: A Retrospective Study Conducted at 25 Centers in Japan (IPRA-CKD)

× Nakamura, Yuta

× Horie, Ichiro

× Yano, Hiroshi

× Nomoto, Hiroshi

× Fukui, Tomoyasu

× Yuyama, Yoshihiko

× Kawamura, Tomoyuki

× Ueda, Mariko

× Yamamoto, Akane

× Hirota, Yushi

× Kusunoki, Yoshiki

× Nishida, Kenro

× Sekiguchi, Dan

× Maeda, Yasutaka

× Minami, Masae

× Nagayama, Ayako

× Iwata, Shimpei

× Minagawa, Hitomi

× Furukawa, Shinya

× Miyake, Teruki

× 上野, 浩晶

× Chinen, Rei

× Nakayama, Yoshiro

× Masuzaki, Hiroaki

× Miyachi, Yasutaka

× Okada, Yosuke

× Okamoto, Mitsuhiro

× Ono, Kaoru

× Tanaka, Ken Ichi

× Kurozumi, Akira

× Sakai, Takenori

× Yamasaki, Hironori

× Yasui, Jun Ichi

× Ito, Ayako

× Kawakami, Atsushi

× Abiru, Norio

Versions

Share

Cite as

Other

エクスポート

コミュニティ